Browsing Tag

Partnering

580 posts

WHO Seeks $31.3 Bn in Funding for COVID-19 Initiatives
By

By
The World Health Organization (WHO) has released a detailed plan that seeks $31.3 billion in funding to support the Access to COVID-19 Tools (ACT) Accelerator, a global collaboration launched by…

Sanofi, Translate Bio Expand Pact for $2.3 Bn to Develop mRNA Vaccines
By

By
Sanofi Pasteur, the vaccines business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to expand their existing 2018 collaboration and license agreement to…

AstraZeneca to Supply Europe with 400 M Doses of COVID-19 Vaccine
By

By
AstraZeneca has reached an agreement with Europe’s Inclusive Vaccines Alliance (IVA), led by Germany, France, Italy and the Netherlands, to supply up to 400 million doses of the University of…

Global Pharma Briefs: News from Asia, Europe and the US
By

By
A roundup of news from Japan (Takeda), the Netherlands (Gilead Sciences) and the US (GSK, Amarin, Apotex). Japan Takeda Receives FDA Warning Letter Takeda has received a Warning Letter from…

Lilly, Evox Therapeutics, in $1.5-Bn Pact for Neurological Therapies
By

By
Eli Lilly and Company and Evox Therapeutics, an Oxford, UK-headquartered biopharmaceutical company, have entered into a research collaboration and license agreement, in a deal worth up to $1.5 billion, to…

Takeda, Neurocrine in $2-Bn Deal To Develop Psychiatric Therapies
By

By
Takeda and Neurocrine Biosciences, a San Diego, California-based pharmaceutical company developing small molecules for neurological and endocrine-related disorders, have entered into a strategic collaboration, in a deal worth up to…

Pharma COVID Roundup: News from Lilly, Gilead, Daiichi Sankyo
By

By
The latest on manufacturing and potential treatments for COVID-19 with news from Lilly, Gilead, Dr. Reddy’s, Daiichi Sankyo, BioNTech, CureVac, Novavax and others. News from Lilly, Dr. Reddy’s, Gilead, Daiichi…

Roche, Innovent in $2.1-Bn Deal for Bispecific Antibodies, Cell Therapies
By

By
Roche and Innovent Biologics, a Suzhou, China-based biopharmaceutical company, have entered into a strategic research and development collaboration in a deal worth up to $2.1 billion (exercise payments totaling $140 million…

AstraZeneca, Accent Enter $1.1 Bn Pact for RNA-Cancer Therapies
By

By
AstraZeneca and Accent Therapeutics, a Lexington, Massachusetts-based biopharmaceutical company developing oncology-focused, small molecule therapies, have formed a deal, worth up to $1.1 billion ($55 million up front and $1.1 billion…

AbbVie, Genmab Enter $3.9-Bn Deal for Bispecific Antibodies
By

By
AbbVie and Genmab, a biopharmaceutical company specializing in antibody therapeutics for treating cancer, have signed a broad collaboration agreement, worth up to $3.9 billion ($750 million up front with the…